Listed

BioLineRx Ltd.: Form 20-F for the period ended Dec 31, 2020

Filed with the SEC on Feb 23, 2021 and accepted by EDGAR at Feb 23, 2021, 12:00 ET.

Share

Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Operating income12 months2020-01-01 to 2020-12-31−$22.9mifrs-full:ProfitLossFromOperatingActivities
Net income12 months2020-01-01 to 2020-12-31−$30.0mifrs-full:ProfitLoss
Operating cash flow12 months2020-01-01 to 2020-12-31−$23.2mifrs-full:CashFlowsFromUsedInOperatingActivities
Cash and equivalentsAt period end2020-12-31$16.8mifrs-full:CashAndCashEquivalents
Current assetsAt period end2020-12-31$22.9mifrs-full:CurrentAssets
Total assetsAt period end2020-12-31$47.3mifrs-full:Assets
Current liabilitiesAt period end2020-12-31$10.6mifrs-full:CurrentLiabilities
Total liabilitiesAt period end2020-12-31$25.3mifrs-full:Liabilities
Shareholders' equityAt period end2020-12-31$22.0mifrs-full:Equity
Shares outstandingAt period end2020-12-31349,169,545 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001178913-21-000741. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.